UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | C000000272 |
|---|---|
| Receipt number | R000000341 |
| Scientific Title | Genome-wide case-control association study to identify susceptibility gene to diabetic nephropathy using single nucleotide polymorphisms. |
| Date of disclosure of the study information | 2005/11/15 |
| Last modified on | 2008/10/21 19:03:26 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Genome-wide case-control association study to identify susceptibility gene to diabetic nephropathy using single nucleotide polymorphisms.
Acronym
Study for susceptibility gene to diabetic nephropathy
Scientific Title
Genome-wide case-control association study to identify susceptibility gene to diabetic nephropathy using single nucleotide polymorphisms.
Scientific Title:Acronym
Study for susceptibility gene to diabetic nephropathy
Region
| Japan |
Condition
Condition
Diabetic nephropathy
Classification by specialty
| Endocrinology and Metabolism | Nephrology |
Classification by malignancy
Others
Genomic information
YES
Objectives
Narrative objectives1
Diabetic nephropathy is the leading cause of end-stage renal disease, accounting for 25% of the patients receiving chronic dialysis therapy. The number of the patients with diabetic nephropathy is expected to continue to increase progressively, giving a serious concern in terms of medical economy. Recently, a large scale genetic approach may be a useful to identify loci involved in the susceptibility for common disorders, as well as in the responsiveness or side-effect of several drugs. Then, in this study to identify genes conferring susceptibility to diabetic nephropathy, we will perform a genomic-wide case-control association study using single nucleotide polymorphisms as genetic markers. Our goal is to provide the evidence showing the novel mechanism of the disease, and to obtain a useful target for new drugs to aid in the prevention and treatment of diabetic nephropathy.
Basic objectives2
Others
Basic objectives -Others
This study explores genes associated with the development and progress of diabetic nephropathy using a database for several hundred thousands of polymorphic markers existing on entire human genome. The results of this study will be expected to establish a method for the prevention and treatment of diabetic nephropathy.
Trial characteristics_1
Exploratory
Trial characteristics_2
Developmental phase
Not applicable
Assessment
Primary outcomes
Diabetic patients with diabetic retinopathy were divided into two groups: 1) nephropathy cases (DN):-patients with overt nephropathy, 2) controls (C):-patients showing no evidence of renal dysfunction (based on the urinary albumin levels). Our first screening involved genotyping 94 DNs and 94 Cs for 10,000 SNP loci, and we further analyzed the SNP loci showing significant differences in allelic frequencies between DN and C using a larger number of patients.
Key secondary outcomes
Base
Study type
Observational
Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| Not applicable |
Age-upper limit
| Not applicable |
Gender
Male and Female
Key inclusion criteria
Type 2 diabetic patients were divided into two groups according to the stage of diabetic nephropathy and diabetic retinopathy.
1) Nephropathy cases:Patients with diabetic retinopathy as well as overt nephropathy, urinary albumin excretion rates (AER) greater than 200 micro-g/min or urinary albumin/creatinine rations (Alb/Cr) greater than 300 mg/gCr, or patients under chronic renal-replacement therapy.
2) Control:Patients with diabetic retinopathy but without any sign of renal dysfunction, AER less than 20 micro-g/min or Alb/Cr less than 30 mg/gCr.
Key exclusion criteria
Patients with other chronic renal diseases.
Target sample size
2000
Research contact person
Name of lead principal investigator
| 1st name | |
| Middle name | |
| Last name | Shiro Maeda |
Organization
SNP Research Center, RIKEN
Division name
Laboratory for Diabetic Nephropathy
Zip code
Address
1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama, Kanagawa 230-0045, Japan
TEL
045-503-9595
Public contact
Name of contact person
| 1st name | |
| Middle name | |
| Last name | Shiro Maeda |
Organization
SNP Research Center, RIKEN
Division name
Laboratory for Diabetic Nephropathy
Zip code
Address
1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama, Kanagawa 230-0045, Japan
TEL
045-503-9595
Homepage URL
smaeda@src.riken.jp
Sponsor or person
Institute
RIKEN
Institute
Department
Personal name
Funding Source
Organization
RIKEN
Organization
Division
Category of Funding Organization
Nationality of Funding Organization
Japan
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Address
Tel
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2005 | Year | 11 | Month | 15 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Date of protocol fixation
| 2001 | Year | 06 | Month | 01 | Day |
Date of IRB
Anticipated trial start date
| 2001 | Year | 06 | Month | 01 | Day |
Last follow-up date
| 2010 | Year | 03 | Month | 01 | Day |
Date of closure to data entry
| 2010 | Year | 03 | Month | 01 | Day |
Date trial data considered complete
Date analysis concluded
| 2010 | Year | 03 | Month | 01 | Day |
Other
Other related information
81,315 SNP loci were successfully genotyped, and about 1,600 SNP loci were found to be statiscally significant (p<0.01). These SNP loci were analyzed further in a larger number of subjects to clarify their statistical significance. As a result, we could identify SLC12A3 and ELMO1 as novel candidates for conferring susceptibility to diabetic nephropathy. We are also examining other candidate loci (p<0.0001).
Management information
Registered date
| 2005 | Year | 10 | Month | 31 | Day |
Last modified on
| 2008 | Year | 10 | Month | 21 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000000341
